Scientists collaborating on drug discovery using AI in a pharmaceutical lab.
OpenAI Group PBC and Novo Nordisk A/S have announced a partnership aimed at accelerating pharmaceutical research and drug delivery. The collaboration will integrate OpenAI’s intelligent agents across Novo Nordisk’s workflow, from lab research to commercial distribution.
The primary goal is to leverage AI to process extensive biological datasets, identify patterns in genomic and clinical trial data, and simulate experiments. This is expected to reduce the time and cost of developing treatments for chronic illnesses like obesity and diabetes.
Novo Nordisk’s President and CEO, Mike Doustdar, emphasized that AI integration will enable faster data analysis and hypothesis testing, leading to quicker market delivery of therapies. Beyond research, AI will optimize manufacturing, supply chain, and distribution operations.
The partnership includes training Novo Nordisk employees to enhance their AI literacy and develop custom tools, adhering to a strict data governance framework with human oversight. Pilot programs are planned across various operations, with a vision for global integration of OpenAI’s models by year-end.
About the Author
